Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

150 trials with published results (11%)

Research Maturity

957 completed trials (71% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

2.8%

38 terminated out of 1345 trials

Success Rate

96.2%

+9.6% vs benchmark

Late-Stage Pipeline

11%

142 trials in Phase 3/4

Results Transparency

16%

150 of 957 completed with results

Key Signals

150 with results96% success38 terminated

Data Visualizations

Phase Distribution

1,207Total
Not Applicable (828)
Early P 1 (9)
P 1 (132)
P 2 (96)
P 3 (102)
P 4 (40)

Trial Status

Completed957
Unknown125
Recruiting86
Active Not Recruiting65
Not Yet Recruiting39
Terminated38

Trial Success Rate

96.2%

Benchmark: 86.5%

Based on 957 completed trials

Clinical Trials (1345)

Showing 20 of 20 trials
NCT06619041Not ApplicableRecruiting

HealthyTogether: RCT of a Dyadic Weight Management Intervention

NCT07738614Phase 1Not Yet Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

NCT06993792Phase 3Active Not Recruiting

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

NCT06325722Not ApplicableRecruitingPrimary

Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change

NCT05929079Phase 3Completed

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

NCT00342732Completed

The Food Intake Phenotype: Assessing Eating Behavior and Food Preferences as Risk Factors for Obesity

NCT07407348Phase 1Recruiting

A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

NCT07225556Phase 1Active Not RecruitingPrimary

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

NCT06972459Phase 3Active Not Recruiting

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

NCT07437079Phase 1RecruitingPrimary

A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

NCT07728669Not ApplicableRecruiting

Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy

NCT07732426Not ApplicableRecruiting

Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies

NCT07497880Phase 2Recruiting

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

NCT07406568Not ApplicableEnrolling By Invitation

Pilot Trial of the Move Healthier Group

NCT00445627Completed

Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus

NCT06904105Phase 3CompletedPrimary

A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity

NCT07400653Phase 3Active Not Recruiting

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

NCT07725809Phase 1Not Yet RecruitingPrimary

A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity

NCT07037433Phase 3Recruiting

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07035093Phase 3Active Not Recruiting

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Scroll to load more

Research Network

Activity Timeline